Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ARQ 197 in Microphthalmia Transcription Factor Associated Tumors
2009-011669-10Phase 2Completed
- Sponsor
- ArQule
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivantinib in Renal cell carcinoma, translocation-associated (tRCC) and clear cell sarcoma (CCS), sponsored by ArQule. Primary endpoints: Overall response rate and Progression-free survival. Started May 2009; status: completed.
02
Drugs
tivantinib
03
Conditions
Renal cell carcinoma, translocation-associated (tRCC)clear cell sarcoma (CCS)
Beyond the preview
Go deeper on 2009-011669-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011669-10.